Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$9.19
-0.12-1.29%
At close: -
$9.19
0.000.00%
After Hours: Jun 20, 4:00 PM EDT
Comments
Loading...
Zenas BioPharma Analyst Ratings and Price Targets | NASDAQ:ZBIO | Benzinga
Zenas BioPharma Inc has a consensus price target of $32.29 based on the ratings of 7 analysts. The high is $45 issued by Guggenheim on March 12, 2025. The low is $19 issued by Wolfe Research on February 4, 2025. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Wedbush, and Guggenheim on May 16, 2025, March 20, 2025, and March 12, 2025, respectively. With an average price target of $36.67 between HC Wainwright & Co., Wedbush, and Guggenheim, there's an implied 298.98% upside for Zenas BioPharma Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Wedbush
Guggenheim
Wolfe Research
Morgan Stanley
1calculated from analyst ratings
Analyst Ratings for Zenas BioPharma
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/16/2025 | Buy Now | 226.44% | HC Wainwright & Co. | Matthew Caufield38% | $30 → $30 | Reiterates | Buy → Buy | Get Alert |
| 03/20/2025 | Buy Now | 280.85% | Wedbush | Martin Fan 51% | → $35 | Initiates | → Outperform | Get Alert |
| 03/12/2025 | Buy Now | 389.66% | Guggenheim | Yatin Suneja55% | $45 → $45 | Reiterates | Buy → Buy | Get Alert |
| 03/12/2025 | Buy Now | 226.44% | HC Wainwright & Co. | Matthew Caufield38% | $30 → $30 | Reiterates | Buy → Buy | Get Alert |
| 02/04/2025 | Buy Now | 106.75% | Wolfe Research | Andy Chen48% | → $19 | Initiates | → Outperform | Get Alert |
| 12/16/2024 | Buy Now | 226.44% | HC Wainwright & Co. | Matthew Caufield38% | → $30 | Initiates | → Buy | Get Alert |
| 12/11/2024 | Buy Now | 280.85% | Morgan Stanley | Vikram Purohit40% | $40 → $35 | Maintains | Overweight | Get Alert |
| 12/03/2024 | Buy Now | — | Guggenheim | Yatin Suneja55% | — | Reiterates | → Buy | Get Alert |
| 10/08/2024 | Buy Now | 193.8% | Citigroup | Yigal Nochomovitz54% | → $27 | Initiates | → Buy | Get Alert |
| 10/08/2024 | Buy Now | 280.85% | Jefferies | Roger Song36% | → $35 | Initiates | → Buy | Get Alert |
| 10/08/2024 | Buy Now | 335.26% | Morgan Stanley | Vikram Purohit40% | → $40 | Initiates | → Overweight | Get Alert |
| 10/08/2024 | Buy Now | 389.66% | Guggenheim | Yatin Suneja55% | → $45 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Zenas BioPharma (ZBIO) stock?
The latest price target for Zenas BioPharma (NASDAQ:ZBIO) was reported by HC Wainwright & Co. on May 16, 2025. The analyst firm set a price target for $30.00 expecting ZBIO to rise to within 12 months (a possible 226.44% upside). 12 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Zenas BioPharma (ZBIO)?
The latest analyst rating for Zenas BioPharma (NASDAQ:ZBIO) was provided by HC Wainwright & Co., and Zenas BioPharma reiterated their buy rating.
When was the last upgrade for Zenas BioPharma (ZBIO)?
There is no last upgrade for Zenas BioPharma
When was the last downgrade for Zenas BioPharma (ZBIO)?
There is no last downgrade for Zenas BioPharma.
When is the next analyst rating going to be posted or updated for Zenas BioPharma (ZBIO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Zenas BioPharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Zenas BioPharma was filed on May 16, 2025 so you should expect the next rating to be made available sometime around May 16, 2026.
Is the Analyst Rating Zenas BioPharma (ZBIO) correct?
While ratings are subjective and will change, the latest Zenas BioPharma (ZBIO) rating was a reiterated with a price target of $30.00 to $30.00. The current price Zenas BioPharma (ZBIO) is trading at is $9.19, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
